Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.
The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders.
About Janssen-Cilag International NV and Janssen-Cilag
Janssen-Cilag International NV and Janssen-Cilag companies have a long track record in developing and marketing treatments for central nervous system disorders, pain management, infectious diseases, gastrointestinal disorders and oncology.
1. National Psoriasis Foundation. About Psoriasis: Statistics. Available at: http://www.psoriasis.org/about/stats. Accessed December 2007
(i) Kim Papp, MD, PhD, Newman Yeilding, MD, Yuhua Wang, PhD, Alexa B. Kimball, MD, MPH, CNTO 1275 (anti-IL-12/23p40) Treatment of Psoriasis: Phase 3 Trial Results, Kim Papp, MD, PhD, Newman Yeilding, MD, Yuhua Wang, PhD, Alexa B. Kimball, MD, MPH, Abstract presented at the AAD 2008, San Antonio.
(ii) Kenneth B. Gordon, MD, Newman Yeilding, MD, Shu Li, MS, Craig Leonardi, MD, Long-term Continuous Maintenance Therapy With CNTO 1275 (anti-IL-12/23p40) as Treatment for Psoriasis: Phase 3 Trial Results, Abstract presented at the AAD 2008, San Antonio.
Investor contacts: Louise Mehrotra, Johnson & Johnson, Phone: +1-732-524-6491; Tina Pinto, Johnson & Johnson, Phone: +1-732-524-2034; Media contact: Satu Schmidt, Janssen-Cilag, Phone: +49-173-746-7682
